Inventor · disambiguated record
Chunping Qiao
Also filed as: QIAO CHUNPING
2 granted patents·19 pending applications·2 citations·filing 2017–2025
43Inventor score
Top patents by PatentIndex Score
21 records- 0185US11547765B2Optimized mini-dystrophin genes and expression cassettes and their useUNIV NORTH CAROLINA CHAPEL HILL·Filed 2020·Granted Jan 10, 2023·2 cites·46 claims
- 0278US12257321B2Optimized mini-dystrophin genes and expression cassettes and their useUNIV NORTH CAROLINA CHAPEL HILL·Filed 2023·Granted Mar 25, 2025·0 cites·14 claims
- 0376US2025367326A1Microdystrophin nucleic acid gene therapy constructs and uses thereofREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0476US2025367328A1Methods of manufacturing microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0576US2025367327A1Treatment of dystrophinopathies with microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0670US2025312492A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0765US2024216543A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2022·Application pending·0 cites
- 0863US2023270886A1Microdystrophin gene therapy constructs and uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 0960US2025288697A1Vectorized anti-tnf-alpha inhibitors for ocular indicationsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1059US2025207126A1Modified muscle-specific promotersREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1158US2024358857A1Treatment of duchenne muscular dystrophy and combinations thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1256US2024384292A1Vectorized tnf-alpha antagonists for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1356US2024309076A1Tau-specific antibody gene therapy compositions, methods and uses thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1456US2024409955A1Auf1 combination therapies for treatment of muscle degenerative diseaseUNIV NEW YORK·Filed 2022·Application pending·0 cites
- 1554US2024218397A1Novel aav vectors and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1650US2025025574A1Engineered nucleic acid regulatory elements and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1750US2024124890A1Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1850US2023391864A1Vectorized anti-tnf-alpha antibodies for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1949US2017368198A1Optimized mini-dystrophin genes and expression cassettes and their useUNIV NORTH CAROLINA CHAPEL HILL·Filed 2017·Application pending·0 cites
- 2043US2023042103A1Engineered nucleic acid regulatory element and methods of uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 2143US2022195462A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →